

SHARIAH GEMS VIRTUAL CONFERENCE TAKEAWAYS

Venture Corporation (VMS SP)

Remains On Track For Growth

VMS continues to see healthy near-term demand from majority of its customers and has an experienced task force to manage the recurring component shortages. Also, its strong R&D capabilities have enabled it to redesign products to reduce dependency on parts that are in shortage. Despite the higher inflationary environment, VMS strives to maintain its net margin in the historical range of 9-10%. Maintain BUY and target price of S\$22.80 (pegged to +1SD, 19.5x 2022F PE).

WHAT'S NEW

- **Continues to see healthy near-term demand from customers.** Venture Corporation (VMS) continues to see healthy demand from most of its customers recently. Despite the increasingly uncertain environment, VMS should be able to deliver relatively resilient performance given its highly diversified customer base across seven technology domains. In addition, most of VMS' customers are in industrial segments such as life science, medical and testing, which are less sensitive to consumer sentiment. Customers are still looking to launch new products to capture more market share. However, in the longer term, some of its customers are turning more cautious due to the increasingly uncertain macro environment.
- **Proactive management and differentiating capabilities help VMS overcome supply chain disruptions.** VMS continues to see component shortages and expects these shortages to ease in 2023. However, VMS does not expect any major disruptions to its production as it has several initiatives to overcome supply chain disruptions, which include: a) redesigning products to reduce dependency on parts that are in shortage, b) working with customers to obtain a longer order forecast for better procurement and production planning, and c) increasing stockpiles of inventories and sharing the working capital burden with customers. Combined with its strong design and R&D capabilities, VMS is able to provide unique solutions to win market share and clients that are of high quality amid this uncertain environment. In addition, VMS is sourcing its components globally and has recently started to see an improvement in the supply of semiconductor chips in China as more local manufacturers are manufacturing their own chips to overcome the supply shortage issues, risk of sanctions and tariffs by the US.
- **Targets to maintain net margin.** Despite the inflationary environment of rising cost of labour and raw materials, VMS aims to maintain a net margin of 9-10%, consistent with its historical trend as it is confident in its ability to manage costs, negotiate higher prices with customers and provide strong value-add to its customers. In addition, VMS is able to source labour from a diversified range of countries given its established presence in Malaysia.

KEY FINANCIALS

Year to 31 Dec (\$m)	2020	2021	2022F	2023F	2024F
Net turnover	3,013	3,107	3,404	3,718	4,037
EBITDA	375	388	419	451	487
Operating profit	334	351	384	417	455
Net profit (rep./act.)	297	312	339	369	402
Net profit (adj.)	297	312	339	369	402
EPS (S cent)	102.3	107.5	116.9	127.0	138.4
PE (x)	16.3	15.5	14.2	13.1	12.0
P/B (x)	1.9	1.8	1.7	1.6	1.5
EV/EBITDA (x)	10.1	9.7	9.0	8.4	7.8
Dividend yield (%)	4.5	4.5	4.8	4.8	4.8
Net margin (%)	9.9	10.0	10.0	9.9	10.0
Net debt/(cash) to equity (%)	(35.9)	(29.7)	(37.8)	(37.2)	(37.3)
ROE (%)	11.7	11.8	12.3	12.7	13.2
Consensus net profit	-	-	352	377	404
UOBKH/Consensus (x)	-	-	0.96	0.98	0.99

Source: VMS, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$16.63
Target Price	S\$22.80
Upside	+37.1%

COMPANY DESCRIPTION

Venture Corporation is a leading global electronics services provider. It provides technology solutions, products and services over a diversified range of high-mix, high-value and complex products.

STOCK DATA

GICS sector	Information Technology
Bloomberg ticker:	VMS SP
Shares issued (m):	291.0
Market cap (\$m):	4,839.5
Market cap (US\$m):	3,479.4
3-mth avg daily t'over (US\$m):	11.7

Price Performance (%)


52-week high/low S\$19.69/S\$16.38

1mth	3mth	6mth	1yr	YTD
(7.2)	(5.4)	(9.2)	(13.4)	(9.2)

Major Shareholders

	%
Wong Ngit Liong	7.1
-	-
-	-
FY22 NAV/Share (S\$)	9.73
FY22 Net Cash/Share (S\$)	3.67

PRICE CHART



Source: Bloomberg

ANALYST(S)

John Cheong
+65 6590 6623
johncheong@uobkayhian.com

STOCK IMPACT

- **VMS remains positive on its long-term growth** as it continues to engage and collaborate with successful and innovative customers in various high-growth, fast expanding market segments.
- **Positive signal from recent share purchases of Executive Chairman.** On 8 Nov 21, Mr Wong Ngit Leong, the Executive Chairman and largest shareholder of VMS, acquired 200,000 shares at S\$18.73/share. Previously, his acquisition of 566,300 shares at an average price of S\$14.45/share from Jul-Sep 17 turned out to be a strong positive signal as VMS' share price hit an all-time high of S\$29.50 in Apr 18.
- **Limited share price downside due to strong balance sheet and good dividends.** As of end-1Q22, VMS had net cash of S\$815m (accounting for about 15% of its current market cap) and led the pack of US-listed peers which were mostly in net debt positions. More importantly, VMS has consistently paid the same amount of dividends or better than that in the preceding years.
- **Positive guidance of key customers:**
 - Broadcom: Expects 1Q22 revenue growth of 14% yoy.
 - NCR: 2022 guidance of 12-15% yoy revenue growth and 27-39% yoy EPS growth.
 - Agilent: 2022 guidance of 7% yoy revenue and EPS growth.
 - Fortive: Expects 2022 revenue growth of 7% yoy.
 - Keysight: Expects 2022 revenue growth of 5% yoy.
 - Illumina: Expects 2022 revenue growth of 14-16% yoy.
 - Waters: Expects 2022 revenue growth of 6% yoy.
 - Philip Morris: Expects 2022 revenue growth of 4-6% yoy and EPS growth of 8-11%.

EARNINGS REVISION/RISK

- We maintain our earnings forecasts.

VALUATION/RECOMMENDATION


- **Maintain BUY and target price of S\$22.80**, pegged at +1SD above its forward mean PE, of 19.5x on 2022F earnings. Currently, VMS offers an attractive dividend yield of 4.7%.

BROAD-BASED YOY GROWTH ACROSS ALL DOMAINS DIVERSIFIED ACROSS >100 CUSTOMERS

Portfolio A	
1. Life Science, Genomics, Molecular Diagnostics and Related Materials Technology	Growth
2. Medical Devices and Equipment	Growth
3. Healthcare & Wellness Technology, Lifestyle Consumer Tech, Health Improvement Products and Others	Growth
Overall Portfolio A Performance	Growth
Portfolio B	
4. Instrumentation, Test & Measurement Technology	Growth
5. Networking & Communications, Security & Safety, Building Automation, Industrial IOT	Flat
6. Advanced Payment Systems	Growth
7. Computing & Productivity Systems, Advanced Industrial Technology, Printing & Imaging, Related Components Technology and Others	Growth
Overall Portfolio B Performance	Growth

Source: VMS

LONG-TERM PE CHART



Source: Bloomberg, UOB Kay Hian

PROFIT & LOSS

Year to 31 Dec (\$m)	2021	2022F	2023F	2024F
Net turnover	3,107.5	3,404.0	3,717.6	4,036.9
EBITDA	387.5	418.9	450.7	487.1
Deprec. & amort.	36.9	35.0	33.3	31.7
EBIT	350.6	383.8	417.4	455.5
Total other non-operating income	2.4	0.8	0.8	0.8
Associate contributions	0.2	0.2	0.2	0.2
Net interest income/(expense)	6.3	6.3	6.3	6.3
Pre-tax profit	359.6	391.2	424.8	462.8
Tax	(47.3)	(51.4)	(55.8)	(60.8)
Minorities	(0.3)	(0.3)	(0.3)	(0.3)
Net profit	312.1	339.5	368.7	401.7
Net profit (adj.)	312.1	339.5	368.7	401.7

BALANCE SHEET

Year to 31 Dec (\$m)	2021	2022F	2023F	2024F
Fixed assets	215.2	215.4	217.3	220.9
Other LT assets	682.6	682.5	682.5	682.4
Cash/ST investment	807.9	1,066.5	1,101.4	1,166.0
Other current assets	1,929.6	1,629.6	1,775.4	1,923.0
Total assets	3,635.3	3,594.0	3,776.5	3,992.3
ST debt	0.0	0.0	0.0	0.0
Other current liabilities	907.5	758.7	804.6	850.6
LT debt	0.0	0.0	0.0	0.0
Other LT liabilities	8.3	8.3	8.3	8.3
Shareholders' equity	2,716.4	2,823.6	2,960.0	3,129.5
Minority interest	3.1	3.4	3.6	3.9
Total liabilities & equity	3,635.3	3,594.0	3,776.5	3,992.3

CASH FLOW

Year to 31 Dec (\$m)	2021	2022F	2023F	2024F
Operating	101.8	519.0	295.3	325.1
Pre-tax profit	359.6	391.2	424.8	462.8
Tax	(55.9)	(51.4)	(55.8)	(60.8)
Deprec. & amort.	36.9	35.0	33.3	31.7
Associates	(0.2)	(0.2)	(0.2)	(0.2)
Working capital changes	(241.5)	151.2	(100.0)	(101.5)
Non-cash items	(0.5)	0.0	0.0	0.0
Other operating cashflows	3.6	(6.8)	(6.8)	(6.8)
Investing	(2.1)	(28.2)	(28.2)	(28.2)
Capex (growth)	(10.8)	(35.0)	(35.0)	(35.0)
Investments	(0.6)	0.0	0.0	0.0
Proceeds from sale of assets	3.0	0.0	0.0	0.0
Others	6.3	6.8	6.8	6.8
Financing	(225.7)	(232.2)	(232.2)	(232.2)
Dividend payments	(217.8)	(232.2)	(232.2)	(232.2)
Issue of shares	(2.8)	0.0	0.0	0.0
Proceeds from borrowings	5.7	0.0	0.0	0.0
Loan repayment	0.0	0.0	0.0	0.0
Others/interest paid	(10.9)	0.0	0.0	0.0
Net cash inflow (outflow)	(126.0)	258.6	34.8	64.7
Beginning cash & cash equivalent	928.7	807.9	1,066.5	1,101.4
Changes due to forex impact	5.2	0.0	0.0	0.0
Ending cash & cash equivalent	807.9	1,066.5	1,101.4	1,166.0

KEY METRICS

Year to 31 Dec (\$m)	2021	2022F	2023F	2024F
Profitability				
EBITDA margin	12.5	12.3	12.1	12.1
Pre-tax margin	11.6	11.5	11.4	11.5
Net margin	10.0	10.0	9.9	10.0
ROA	9.1	9.4	10.0	10.3
ROE	11.8	12.3	12.7	13.2
Growth				
Turnover	3.1	9.5	9.2	8.6
EBITDA	3.2	8.1	7.6	8.1
Pre-tax profit	4.9	8.8	8.6	9.0
Net profit	5.0	8.8	8.6	9.0
Net profit (adj.)	5.0	8.8	8.6	9.0
EPS	5.1	8.8	8.6	9.0
Leverage				
Debt to total capital	0.0	0.0	0.0	0.0
Debt to equity	0.0	0.0	0.0	0.0
Net debt/(cash) to equity	(29.7)	(37.8)	(37.2)	(37.3)

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W